Journal of Clinical Psychopharmacology最新文献_第10页

Journal of Clinical Psychopharmacology Updates. 临床精神药理学杂志》更新。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 DOI: 10.1097/JCP.0000000000001913

Anthony J Rothschild

引用次数: 0

Plasma Clozapine and N -Desmethylclozapine (Norclozapine) Concentrations and the Clozapine/Norclozapine Ratio : Effect of Dose, Sex, and Cigarette Smoking. 血浆氯氮平和 N-去甲氯氮平（诺氯氮平）浓度以及氯氮平/诺氯氮平比率：剂量、性别和吸烟的影响。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-22 DOI: 10.1097/JCP.0000000000001909

Robert James Flanagan, Stephen John Obee, Alice Hyun Min Kim, Susanna Every-Palmer

{"title":"Plasma Clozapine and N -Desmethylclozapine (Norclozapine) Concentrations and the Clozapine/Norclozapine Ratio : Effect of Dose, Sex, and Cigarette Smoking.","authors":"Robert James Flanagan, Stephen John Obee, Alice Hyun Min Kim, Susanna Every-Palmer","doi":"10.1097/JCP.0000000000001909","DOIUrl":"10.1097/JCP.0000000000001909","url":null,"abstract":"Background: Smoking enhances plasma clozapine clearance, but the magnitude of the effect across the dose and age ranges is unclear.Methods: We audited clozapine dose and predose plasma clozapine and N -desmethylclozapine (norclozapine) concentrations by sex and smoking habit in samples submitted for clozapine TDM, 1996-2017.Results: There were 105,316/60,792 and 34,288/31,309 samples from male/female smokers/nonsmokers, respectively. There were distinct dose-median plasma concentration trajectories for male/female smokers/nonsmokers across the range <50 to >850 mg d -1 . For both sexes, the percentage difference in median plasma clozapine in nonsmokers versus smokers averaged 50% but was greatest for men (76%) and women (59%) in the 151 to 250 mg d -1 dose band. In men, the percentage difference declined steadily to 34% at doses of ≥850 mg d -1 . In women, the difference after falling initially remained relatively constant at 40% to 54%. The pattern in median plasma clozapine/norclozapine ratio by plasma clozapine concentration and dose groups was independent of sex and smoking habit, but increased with plasma clozapine concentration (higher ratio at higher concentrations) and also changed with dose. Median plasma clozapine concentration and median clozapine dose by sex and smoking habit were similar up to age 60 years. Proportional weight gain was similar over time in smokers and nonsmokers of either sex.Implications: These data explain the variations in the effect size of starting or stopping smoking on plasma clozapine concentration at constant dose reported in different studies. Changes in smoking habit in patients prescribed clozapine require prompt dose adjustment.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"492-501"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice. 精神病临床高危人群的抗精神病治疗：对临床实践建议的叙述性回顾。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1097/JCP.0000000000001891

Alessandro Di Lisi, Simona Pupo, Marco Menchetti, Lorenzo Pelizza

{"title":"Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice.","authors":"Alessandro Di Lisi, Simona Pupo, Marco Menchetti, Lorenzo Pelizza","doi":"10.1097/JCP.0000000000001891","DOIUrl":"10.1097/JCP.0000000000001891","url":null,"abstract":"Purpose: The \"early intervention\" paradigm in psychiatry holds significant promise for preventing psychosis. Recent evidence showed that individuals at clinical high risk for psychosis (CHR-P) with antipsychotic (AP) prescription at baseline have higher psychosis transition rates compared with those without AP, although the underlying cause remains unclear. In this article, we reviewed international guidelines on early intervention in CHR-P people, paying specific attention to clinical recommendations on AP treatment. Then, we comment on these suggestions in the light of recent empirical evidence examining AP prescription in CHR-P populations within \"real-world\" clinical settings.Methods: This search was conducted on PubMed/MEDLINE, PsycINFO, EMBASE, and Google, looking for both \"Guidelines AND CHR-P OR UHR OR Early Psychosis.\"Results: International guidelines generally recommend not using AP as first-line treatment, but only when psychosocial interventions have failed. CHR-P people with AP drug showed high prevalence rates and had more severe clinical picture at entry. Is this a \"warning signal\" for potentially higher psychosis transition risk? Is it a direct AP iatrogenic effect? Is it possible to detect specific CHR-P subgroup that may benefit from AP? These are the questions that this article seeks to explore.Conclusions: The current framework for identifying CHR-P subjects has defined psychometric criteria mainly based on positive symptoms. In our opinion, this is reductive, especially for evaluating therapeutic outcomes and prognosis. A more comprehensive assessment considering quality of life, psychiatric comorbidity, persistent negative symptoms, subjective experience of CHR-P psychopathology, and social/personal recovery is thus needed.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"44 5","pages":"502-508"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Painful Ejaculation Associated With Atomoxetine and Bupropion: A Case Report. 与阿托莫西汀和安非他酮相关的射精疼痛：病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001894

Priyadarshini Bera, Deeksha Chakrabarty, Sivapriya Vaidyanathan

引用次数: 0

Question: How Should I Switch From One Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to Another SSRI or SNRI in a Patient With Major Depressive Disorder? 问：重度抑郁障碍患者应该如何从一种选择性羟色胺再摄取抑制剂（SSRI）或羟色胺和去甲肾上腺素再摄取抑制剂（SNRI）切换到另一种 SSRI 或 SNRI？

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-22 DOI: 10.1097/JCP.0000000000001907

Anthony J Rothschild

引用次数: 0

Mania Associated With Cariprazine: A Case Report and a Review of Literature Regarding Bipolar Depression Treatment With Cariprazine. 与卡哌嗪有关的躁狂症：一份病例报告以及有关用卡普拉嗪治疗躁郁症的文献综述。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001892

Luís Pedro Paulino Ferreira, Carolina Martins Batista, João Carlos Machado Nogueira, Maria Amélia Silva Aleixo

引用次数: 0

Late Recognition of Cholinergic Delirium in Patient on Donepezil Combination Treatment. 多奈哌齐联合疗法患者胆碱能谵妄的后期识别。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-16 DOI: 10.1097/JCP.0000000000001901

Naomi Gwynn, Jean-Pierre Lindenmayer, Thomas Boes, Christian Pitalo

引用次数: 0

Comparison of Weight-Based Valproic Acid Dosing in Treatment of Mental Illness Among Obese and Nonobese Patients. 基于体重的丙戊酸剂量在治疗肥胖和非肥胖精神疾病患者中的比较。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001883

Cindy Trac, Angeleki Zecopoulos, Clint Ross, Erin Weeda, Dan McGraw

{"title":"Comparison of Weight-Based Valproic Acid Dosing in Treatment of Mental Illness Among Obese and Nonobese Patients.","authors":"Cindy Trac, Angeleki Zecopoulos, Clint Ross, Erin Weeda, Dan McGraw","doi":"10.1097/JCP.0000000000001883","DOIUrl":"10.1097/JCP.0000000000001883","url":null,"abstract":"Purpose/background: A weight-based dosing approach of 20-30 mg/kg per day of valproic acid (VPA) has been shown to achieve rapid attainment of mood symptom control. Due to interindividual pharmacokinetic variability, therapeutic drug monitoring may be a useful tool to avoid VPA toxicity. Limited research exists on the impact of patient body weight on VPA pharmacokinetic profiles. This analysis aims to explore the correlation between steady-state serum levels of VPA and weight-based dosing strategies, including total body weight (TBW), ideal body weight (IBW), and adjusted body weight (AdjBW), between obese and nonobese patients.Methods/procedures: This single-center, retrospective, observational cohort analysis evaluated weight-based dosing of VPA in obese and nonobese patients admitted to inpatient psychiatry at a large academic medical center between July 1, 2017, and July 1, 2022.Findings/results: This analysis included 93 obese and 93 nonobese patients. No significant difference in median VPA serum concentrations was observed between groups ( P = 0.82). However, the obese group received a lower median weight-based dose (15.6 mg/kg) compared with the nonobese group (19.5 mg/kg, P < 0.001). A stronger correlation was found between VPA dose and therapeutic serum levels in the obese group compared with the nonobese group regardless of weight-based dosing strategy. Dosing with AdjBW in obese patients most closely approximated dosing with TBW in nonobese patients.Implications/conclusions: In obese patients, our analysis suggests dosing VPA using AdjBW may be considered as the preferred dosing strategy over IBW or TBW to minimize toxicity risk. Further research is needed with larger sample sizes and diverse patient populations to confirm these findings.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"468-471"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar Disorder. JNJ-18038683 对稳定型双相情感障碍患者的认知障碍缺乏疗效

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 DOI: 10.1097/JCP.0000000000001889

Mahdi Arshadi, Ahmed Z Elmaadawi, Suhayl Nasr, Karu Jayathilake, Stefanie Rassnick, Lisa Ford, Wayne C Drevets, Herbert Y Meltzer

{"title":"Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar Disorder.","authors":"Mahdi Arshadi, Ahmed Z Elmaadawi, Suhayl Nasr, Karu Jayathilake, Stefanie Rassnick, Lisa Ford, Wayne C Drevets, Herbert Y Meltzer","doi":"10.1097/JCP.0000000000001889","DOIUrl":"10.1097/JCP.0000000000001889","url":null,"abstract":"Background: The serotonin type 7 (5-HT7) receptor is one of 14 5-HT receptors. It has received attention for its possible role in mood disorders and cognition. The 5-HT7 receptor antagonist, JNJ-18038683, has been reported to be effective in rodent models of depression and REM sleep. Also, 5-HT7 receptor blockade has been postulated to be a key component of cognitive enhancement in a number of drugs. Bipolar disorder (BD) usually endures cognitive impairment (CI); however, no treatment for CI in BD has been approved. This study aimed to evaluate the efficacy of JNJ-18038683 to improve the CI of BD compared to a placebo.Methods: We conducted a placebo-controlled, 8-week trial of JNJ-18038683 in BD patients. Each patient's data were analyzed and reassessed blindly with a comprehensive neuropsychological battery, depression and hypomania ratings, and overall social and work function measures.Results: Of 60 patients, 38 (63%) were female, 43 (72%) had BD type 1, and most patients were Caucasian and married. The overall time effect for the combined group shows statistically significant improvement from baseline to week 8 for most of the neurocognitive battery measures. This indicates a significant improvement in psychopathology and cognition during the study time in both JNJ-18038683 and placebo groups, but no difference between groups.Conclusions: This study showed no efficacy for the improvement of CIBD or mood symptoms with JNJ-18038683 compared to the placebo.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"44 5","pages":"481-491"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atomoxetine Associated Activation Syndrome in Adolescent Patients With ADHD. 青少年多动症患者的阿托莫西汀相关激活综合征。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-06-21 DOI: 10.1097/JCP.0000000000001875

Harsh Khandelwal, Khushi Jain, Akshaya B Raj, Aakash Chahar, Surendra Singh Rajpurohit, Deepika Biyyala, Naresh Nebhinani, Navratan Suthar, Puneet Soni, Tanu Gupta

引用次数: 0